Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness. (28th June 2018)

• Record Type: Journal Article
• Authors: Venkatesan, Sudhir; Carias, Cristina; Biggerstaff, Matthew; Campbell, Angela P; Nguyen-Van-Tam, Jonathan S; Kahn, Emily; Myles, Puja R; Meltzer, Martin I
• Is Part Of: Journal of public health. Volume 41:Number 2(2019:Jun.)
• Page Start: 379
• Page End: 390
• Publication Date: 2018-06-28
• Subjects: cost-effectiveness -- decision tree -- neuraminidase inhibitors -- pandemic influenza; Public health -- Periodicals; Public health -- Great Britain -- Periodicals; Medical policy -- Periodicals; Medical policy -- Great Britain -- Periodicals; 362.1
• DOI: 10.1093/pubmed/fdy108
• Languages: English
• ISSNs: 1741-3842

Abstract

Abstract: Background: Many countries have acquired antiviral stockpiles for pandemic influenza mitigation and a significant part of the stockpile may be focussed towards community-based treatment. Methods: We developed a spreadsheet-based, decision tree model to assess outcomes averted and cost-effectiveness of antiviral treatment for outpatient use from the perspective of the healthcare payer in the UK. We defined five pandemic scenarios—one based on the 2009 A(H1N1) pandemic and four hypothetical scenarios varying in measures of transmissibility and severity. Results: Community-based antiviral treatment was estimated to avert 14–23% of hospitalizations in an overall population of 62.28 million. Higher proportions of averted outcomes were seen in patients with high-risk conditions, when compared to non-high-risk patients. We found that antiviral treatment was cost-saving across pandemic scenarios for high-risk population groups, and cost-saving for the overall population in higher severity influenza pandemics. Antiviral effectiveness had the greatest influence on both the number of hospitalizations averted and on cost-effectiveness. Conclusions: This analysis shows that across pandemic scenarios, antiviral treatment can be cost-saving for population groups at high risk of influenza-related complications.